Karyopharm Therapeutics Inc(KPTI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:57 PM ET (Korea 10/31 08:57)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -13.08 | Insider Own | 16.91% | Shs Outstand | 22.7M | Perf Week | 27.92% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | 53.13% | Insider Trans | -0.23% | Shs Float | 18.9M | Perf Month | -23.63% |
| Enterprise Value | 0.21B | PEG | - | EPS next Q | -0.95 | Inst Own | 80.65% | Short Float | 38.55% | Perf Quarter | -66.4% |
| Income | -0.22B | P/S | 0.1 | EPS this Y | 72.99% | Inst Trans | 10.82% | Short Ratio | 2.52 | Perf Half Y | -92.45% |
| Sales | 0.15B | P/B | - | EPS next 5Y | 60.92% | ROA | -207.9% | Short Interest | 7.27M | Perf YTD | -91.01% |
| Book/sh | -14.56 | P/C | 0.23 | EPS past 3/5Y | 16.03% 15.19% | ROE | - | 52W High | -93.98% ($10.99) | Perf Year | -88.89% |
| Cash/sh | 2.87 | P/FCF | - | Sales past 3/5Y | -2.39% 6.21% | ROIC | - | 52W Low | 113.55% ($0.31) | Perf 3Y | -94.62% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 11.95% | Gross Margin | 95.89% | Volatility(W/M) | 42.93% 25.42% | Perf 5Y | -99.19% |
| Dividend TTM | - | EV/Sales | 1.41 | Sales Y/Y TTM | 6.81% | Oper. Margin | -56.17% | ATR (14) | 0.16 | Perf 10Y | -99.41% |
| Dividend Ex-Date | - | Quick Ratio | 0.76 | EPS Q/Q | 46.41% | Profit Margin | -153.28% | RSI (14) | 42.99 | Recom | 1.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.79 | Sales Q/Q | -11.86% | SMA20 | 23.88% ($0.53) | Beta | 1.09 | Target Price | $8.8 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/13 | SMA50 | -45.83% ($1.22) | Rel Volume | 1.22 | Prev Close | $0.88 |
| Employees | 228 | LT Debt/Eq | - | EPS/Sales Surpr. | -69.13% 3.85% | SMA200 | -89.03% ($6.02) | Avg Volume(3M) | 2.89M | Price | $0.66 |
| IPO | 2013/11/6 | Option/Short | Yes/Yes | Trades | 5737 | Volume | 3,523,445 | Change | -24.76% |
💊 A US biotech company that develops and commercializes oral anticancer drugs targeting nuclear export proteins. It has commercialized its lead drug selinexor (brand name XPOVIO) for multiple myeloma and other indications, and is focused on a pipeline of novel drugs to expand into myelofibrosis, endometrial cancer, and additional indications.
Over the past 1 year, on the lower side
94% below its 1-year high.
Traded about as much as usual. That is 122% of its average volume.
KPTI has weak earning power
Of every $100 in sales, $56.17 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +73.0% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $10. Peers typically go for $1,010.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.2%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
38.5% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #479 of 597 in the industry
Based on market cap of $15M.
PLUR#476 Pluri Inc $16M PER - 
DYAI#477 Dyadic International Inc, DE $15M PER - 
ABOS#478 Acumen Pharmaceuticals Inc $15M PER - KPTI#479 Karyopharm Therapeutics Inc $15M PER - 
AKTX#480 Akari Therapeutics Plc ADR $14M PER - 
FAQ
What kind of company is KPTI?
KPTI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KPTI?
The market cap of KPTI is approximately $15M, ranking 5,299 within its sector.
What is the 52-week high and low for KPTI?
KPTI has recorded a 52-week high of $10.99 and a low of $0.31.
